Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy.
N HaddadJ DelyonS Trabelsi MessaiF HermsM T LecciaC LebbeJ WhitneyS BhatiaNicole Basset-SeguinPublished in: The British journal of dermatology (2020)